Information  X 
Enter a valid email address

XTL Biopharm Ltd (XTL)

  Print      Mail a friend

Thursday 29 September, 2005

XTL Biopharm Ltd

Initiation of Phase 1a Clinical Trial of XTL-6865


XTLbio has initiated the Phase 1a clinical trial of XTL-6865 for the treatment 
                                of hepatitis C                                 

Rehovot, Israel, 29 September 2005 - XTL Biopharmaceuticals Ltd ('XTLbio')
(LSE: XTL; NASDAQ: XTLB) today announced that it has initiated the Phase1a
clinical trial of XTL-6865 for the treatment of hepatitis C ('HCV'). This trial
is being conducted under an investigational new drug application ('IND'), filed
with the Food and Drug Administration ('FDA') in April this year. The trial is
a multi-center trial and will be conducted in the US and Israel.


XTL-6865 is being developed to prevent HCV re-infection following a liver
transplant and for the treatment of chronic HCV disease. XTL-6865 is a
combination of two fully human monoclonal antibodies (Ab68 and Ab65) against
the hepatitis C virus E2 envelope protein. A single antibody version of this
product was tested in a pilot clinical program that included both Phase I and
Phase II clinical trials and provided preliminary evidence of anti-viral
activity in humans.

Michael Weiss, XTLbio's Chairman, commented:


'Earlier this year, we set the initiation of clinical trials with XTL-6865 as a
significant corporate milestone for 2005. We are very pleased to have
accomplished this milestone, and look forward to the further advancement of
this important product in our HCV portfolio'

Contacts:

XTLbio

Jonathan Burgin, Chief Financial Officer Tel: +972 8 930 4440

About XTL Biopharmaceuticals Ltd.

XTL Biopharmaceuticals Ltd. (XTLbio) is a biopharmaceutical company developing
drugs against hepatitis. Established in 1993, XTLbio became a public company in
2000 and its ordinary shares are listed on the Official List of the UK Listing
Authority and are traded on the London Stock Exchange under the symbol XTL and
on the Tel Aviv Stock Exchange, Israel, and ADR's, representing 10 ordinary
shares each, are traded on The NASDAQ Stock Market under the symbol XTLB.

Cautionary Statement

Some of the statements included in this press release may be forward-looking
statements that involve a number of risks and uncertainties. For those
statements, we claim the protection of the safe harbor for forward-looking
statements contained in the US Private Securities Litigation Reform Act of
1995. Among the factors that could cause our actual results to differ
materially, and therefore affect interest by investors in our securities, are
the following: the results of prior trails with XTL-686are not necessarily
indicative of the results we may have in the Phase 1a and 1b trials; and other
risk factors identified from time to time in our reports filed with the various
regulatory bodies. Any forward-looking statements set forth in this press
release speak only as of the date of this press release. We do not intend to
update any of these forward-looking statements to reflect events or
circumstances that occur after the date hereof. This press release and prior
releases are available at www.xtlbio.com. The information in our website is not
incorporated by reference into this press release and is included as an
inactive textual reference only.


                                                                                                                                         

a d v e r t i s e m e n t